PINAZ 5MG TABLET Overview
Pinaz 5mg is atypical antipsychotic agent similar in chemical structure and in mechanism of action to clozapine. The development of it was based on the atypical profile of clozapine which suggests that the antipsychotic effects are due to clozapine’s interaction at a number of different receptors rather than at a single receptor type Like clozapine, it bindsto, dopamine, histamine (H-1), muscarinic, and serotonin type 2 (5-HTA) receptors. It has a reduced incidence of extrapyramidal reactions and appears to have a low potential for drug interactions. Clinically, it may be effective for both negative and positive symptoms of schizophrenia. Final FDA approval was granted October 1, 1996 for the treatment of schizophrenia.
Indications
Pinaz is primarily indicated in conditions like Nausea and vomiting Psychosis, Schizophrenia, and can also be given in adjunctive therapy as an alternative drug of choice in Mania
Contraindication Pinaz is contraindicated in conditions like Narrow-angle glaucoma
Side Effects
The severe or irreversible adverse effects of Pinaz which give rise to further complications include Seizures, Extrapyramidal syndrome. The symptomatic adverse reactions produced by Pinaz are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Constipation, Dry mouth, Peripheral edema, Weight gain, SomnolenceX, Increased appetite, Orthostatic hypotension, Dry mouth, dizziness.
Warnings Olanzepine should be used with caution in patients with liver or heart disease, low blood pressure, breast cancer, stroke, diabetes, seizures (any neurological problems). prostate problems, narrow angle glaucoma, intestinal disease or any allergy. Caution is advised to avoid overheating and also excessive body water loss by very strenuous exercise or exposure to extreme heat. Alcohol use may add to the dizziness and drowsiness effect of this drug. It should be used with caution in the elderly. It should be used only when clearly needed during pregnancy
High Risk Groups
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies
Reviews
There are no reviews yet.